Evidence map›Paper›PMID 38605291›Full record

ArticleBMC cancer2024

Exploring the relationship between Treg-mediated risk in COPD and lung cancer through Mendelian randomization analysis and scRNA-seq data integration.

Dengfeng Zhang, Haitao Liu, Fangchao Zhao, Pengfei Guo, Jing Li, Tianxing Lu, Zhirong Li, Shujun Li

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Dengfeng Zhang *Provincial Center for Clinical Laboratories,Department of Thoracic Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang, China.
Haitao Liu *College of Life Science, Inner Mongolia University, Hohhot, China.
Fangchao ZhaoProvincial Center for Clinical Laboratories,Department of Thoracic Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang, China.
Pengfei GuoProvincial Center for Clinical Laboratories,Department of Thoracic Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang, China.
Jing LiProvincial Center for Clinical Laboratories,Department of Thoracic Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang, China.
Tianxing LuProvincial Center for Clinical Laboratories,Department of Thoracic Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang, China.
Zhirong LiProvincial Center for Clinical Laboratories,Department of Thoracic Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang, China. lizhirong@hebmu.edu.cn.
Shujun LiProvincial Center for Clinical Laboratories,Department of Thoracic Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang, China. lishujun2333@163.com.
Hebei Medical University · CNInner Mongolia University · CN

Funding

Hebei Provincial Government sponsored the project of training excellent talents in clinical medicine No. 303-2022-27-37Science and Technology Plan Project of Hebei Province No.223777106D
6 · The paper itself

Abstract

backgroundEvidence from observational studies suggests an association between chronic obstructive pulmonary disease (COPD) and lung cancer. The potential interactions between the immune system and the lungs may play a causative role in COPD and lung cancer and offer therapeutic prospects. However, the causal association and the immune-mediated mechanisms between COPD and lung cancer remain to be determined.

methodsWe employed a two-sample Mendelian randomization (MR) approach to investigate the causal association between COPD and lung cancer. Additionally, we examined whether immune cell signals were causally related to lung cancer, as well as whether COPD was causally associated with immune cell signals. Furthermore, through two-step Mendelian randomization, we investigated the mediating effects of immune cell signals in the causal association between COPD and lung cancer. Leveraging publicly available genetic data, our analysis included 468,475 individuals of European ancestry with COPD, 492,803 individuals of European ancestry with lung cancer, and 731 immune cell signatures of European ancestry. Additionally, we conducted single-cell transcriptome sequencing analysis on COPD, lung cancer, and control samples to validate our findings.

findingsWe found a causal association between COPD and lung cancer (odds ratio [OR] = 1.63, 95% confidence interval [CI] = 1.31-2.02, P-value < 0.001). We also observed a causal association between COPD and regulatory T cells (odds ratio [OR] = 1.19, 95% confidence interval [CI] = 1.01-1.40, P-value < 0.05), as well as a causal association between regulatory T cells and lung cancer (odds ratio [OR] = 1.02, 95% confidence interval [CI] = 1.002-1.045, P-value < 0.05). Furthermore, our two-step Mendelian randomization analysis demonstrated that COPD is associated with lung cancer through the mediation of regulatory T cells. These findings were further validated through single-cell sequencing analysis, confirming the mediating role of regulatory T cells in the association between COPD and lung cancer.

interpretationAs far as we are aware, we are the first to combine single-celled immune cell data with two-sample Mendelian randomization. Our analysis indicates a causal association between COPD and lung cancer, with regulatory T cells playing an intermediary role.

Indexed as

Lung NeoplasmsPulmonary Disease, Chronic ObstructiveGenome-Wide Association StudyHumansMendelian Randomization AnalysisSingle-Cell Gene Expression AnalysisT-Lymphocytes, RegulatoryChronic obstructive Pulmonary diseaseLung cancerMendelian randomizationRegulatory T cellsscRNA-seq

Identifiers

PMID38605291
PMCPMC11010300
OpenAlexW4394716514

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.